The introduction of universal passive immunisation with nirsevimab, a long-acting monoclonal antibody, led to significant reductions in hospitalizations and paediatric intensive care admissions for respiratory syncytial virus-associated lower respiratory tract infections (RSV-LRTIs), particularly benefiting infants younger than 6 months.
"These findings are encouraging, and it is anticipated that in the coming years, nirsevimab prophylaxis will mitigate the significant burden on healthcare services during the winter season," the authors wrote.
The study was led by Lorena Bermúdez-Barrezueta, Faculty of Medicine, Valladolid University, Valladolid, Spain. It was published online on May 16, 2025, in the European Journal of Pediatrics.
This was a single-centre study with a limited sample size.
The study was supported by FEDER European Funds and the Junta de Castilla y León under the Research and Innovation Strategy for Smart Specialization and partially funded by the Ernesto Sanchez Villares Foundation.